CS0159 ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
93	原発性胆汁性胆管炎	1
94	原発性硬化性胆管炎	1

93. 原発性胆汁性胆管炎

---

臨床試験数 : 298 /  薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05624294 (ClinicalTrials.gov)	December 19, 2022	14/11/2022	Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects	A Phase I, Randomized, Double-blind, Placebo-controlled, Single Ascending Does/ Mulelple Ascending Does Study of CS0159 to Evaluate the Safety, Tolerability, Pharmacokynetics, and Food Effect in Healthy Subjects	Primary Biliary Cholangitis	Drug: CS0159;Drug: Placebo	Cascade Pharmaceuticals, Inc	NULL	Recruiting	18 Years	55 Years	All	36	Phase 1	China

94. 原発性硬化性胆管炎

---

臨床試験数 : 148 /  薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05082779 (ClinicalTrials.gov)	October 26, 2021	25/9/2021	Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159	A Phase I, Randomized, Double-Blind, Placebo-Contralled, Single Asending Dose / Multiple Ascending Dose Study of CS0159 to to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Effect Food in Healthy Subject	Primary Sclerosing Cholangitis (PSC)	Drug: CS0159	Cascade Pharmaceuticals, Inc	Covance	Completed	18 Years	55 Years	All	79	Phase 1	United States